Article Details

BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies

Retrieved on: 2024-02-08 20:56:11

Tags for this article:

Click the tags to see associated articles and topics

BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies. View article details on hiswai:

Excerpt

Meanwhile, BioNTech will gain access to Autolus's cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo ...

Article found on: medcitynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo